risk of no improvement, 88.0% lower, RR 0.12, p < 0.001, treatment 3 of 40 (7.5%), control 25 of 40 (62.5%), NNT 1.8, mid-recovery day 7.
risk of no improvement, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 40 (0.0%), control 4 of 40 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.18, treatment 6 of 40 (15.0%), control 12 of 40 (30.0%), NNT 6.7.
Abstract: COVID-19 - TOPICAL SUBJECT
Science & Healthcare, 2021 (Vol. 23) 4
Received: 28 June 2021 / Accepted: 02 August 2021 / Published online: 31 August 2021
CLINICAL EFFICACY OF THE ANTIVIRAL DRUG FAVIPIRAVIR
IN THE COMPLEX TREATMENT OF PATIENTS
WITH COVID-19 CORONAVIRUS INFECTION
Sholpan A. Kulzhanova1, https://orcid.org/000-0002-4118-4905
Nurlan Е. Aukenov 2, https://orcid.org/0000-0002-3163-2997
Maiya E. Konkayeva1, https://orcid.org/0000-0002-1634-3855
Zauresh K. Smagulova1,
Gulnara T. Tuleshova1, https://orcid.org/0000-0002-7309-5165
Saule B. Maukayeva3, http://orcid.org/ 0000-0002-2679-6399
Nazira Ye. Beisenbieva1,
Gulsimzhan O. Turebaeva1,
Gaukhar A. Nurakhmetova1, https://orcid.org/ 0000-0002-3279-9350
Aigul M. Utegenova1, https://orcid.org/ 0000-0002-5777-3747
NJSC “Astana Medical University”, Nur-Sultan, Republic of Kazakhstan;
Ministry of Health of the Republic of Kazakhstan, Nur-Sultan, Republic of Kazakhstan;
NJSC “Semey Medical University”, Semey, Republic of Kazakhstan.
Introduction. It is known that most patients with COVID-19 have a disease of mild to moderate severity and can be
treated at home. A potential etiotropic drug in the treatment of such patients is favipiravir. To finally decide on the inclusion of
this drug in the international recommendations for the treatment of COVID-19, further studies are needed to assess its
effectiveness and safety in patients with COVID-19.
The aim of the study was to study the clinical efficacy of favipiravir in the complex therapy of patients with moderateseverity COVID-19 coronavirus infection.
Materials and methods. A retrospective analysis of 468 medical records of an inpatient patient with a moderate form of
coronavirus infection COVID-19, who were treated at the State Clinical Hospital at the Multi-Specialty Medical Center of the
Akimat of Nur-Sultan, the Semey Infectious Diseases Hospital, for the period August-October 2020, was carried out.
The experimental (main) group consisted of 40 patients with COVID-19 of moderate severity, who, in addition to standard
therapy in accordance with the Clinical Protocol for Diagnosis and Treatment "COVID-19 Coronavirus infection (10th edition
with changes from 15.07.2020), were prescribed oral favipiravir at a dose of 1600 mg/12 h on day 1, then 600 mg/12 h on
the following days, for a total of 7 days. The comparison group (control group) consisted of 40 patients with moderate CVI
who did not receive favipiravir.
Descriptive statistics were performed with the calculation of the mean (M) and standard deviation (SD) for quantitative
variables; percentages were calculated for qualitative variables. Statistical analysis was performed using Microsoft Excel and
IBM SPSS Statistics 20.0. P <0.05 was considered statistically significant.
Results and discussion. The present study showed that the early initiation of antiviral therapy with Favipiravir,
compared with standard therapy without an antiviral drug, in patients with a moderate form of COVID-19 is associated with a
statistically significant clinical improvement and a large percentage of virus elimination from the mucous membranes of the
upper respiratory tract according to molecular genetic research. In the group of patients receiving favipiravir, complete
remission of the disease with normalization of the main clinical parameters and the absence of complaints for 7 days of
hospitalization was significantly more often than in..
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.